Lucid Capital analyst Elemer Piros initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $8 price target The company is developing chronic steroid treatments for rare diseases with “blockbuster potential,” the analyst tells investors in a research note. The firm believes the company’s EryDex is set to become a blockbuster treatment in the lead ataxia-telangiectasia indication alone.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX: